Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16179
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKnezevic, Brittany-
dc.contributor.authorSprigg, Dustin-
dc.contributor.authorSeet, Jason-
dc.contributor.authorTrevenen, Michelle-
dc.contributor.authorTrubiano, Jason-
dc.contributor.authorSmith, William-
dc.contributor.authorJeelall, Yogesh-
dc.contributor.authorVale, Sandra-
dc.contributor.authorLoh, Richard-
dc.contributor.authorMcLean-Tooke, Andrew-
dc.contributor.authorLucas, Michael-
dc.date2016-08-17-
dc.date.accessioned2016-09-05T05:13:49Z-
dc.date.available2016-09-05T05:13:49Z-
dc.date.issued2016-11-
dc.identifier.citationInternal Medicine Journal 2016; 46(11): 1276-1283en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16179-
dc.description.abstractBACKGROUND: Patients frequently report antibiotic allergies, however only 10% of labelled patients have a true allergy. AIM: We investigated the documentation of antibiotic "allergy" labels (AALs) and the effect of labelling on clinical outcomes, in a West Australian adult tertiary hospital. METHODS: Retrospective cross-sectional analysis of patients captured in the 2013 and 2014 National Antimicrobial Prescribing Surveys. Data was collected on documented antibiotic adverse drug reactions, antibiotic cost, prescribing appropriateness, prevalence of multi-drug resistant organisms, length of stay, intensive care admission, and readmissions. RESULTS: Of 687 patients surveyed, 278 (40%) were aged 70 or above, 365 (53%) were male and 279 (41%) were prescribed antibiotics. AALs were recorded in 122 (18%) patients and the majority were penicillin labels (n = 87; 71%). Details of AALs were documented for 80 of 141 (57%) individual allergy labels, with 61 describing allergic symptoms. Patients with beta-lactam allergy labels received fewer penicillins (p = 0.0002) and more aminoglycosides (p = 0.043) and metronidazole (p = 0.021) than patients without beta-lactam labels. Five patients received an antibiotic that was contraindicated according to their allergy status. Patients with AALs had significantly more hospital readmissions within 4 weeks (p = 0.001) and 6 months (p = 0.025) of discharge, compared with unlabelled patients. The majority (81%) of readmitted labelled patients had major infections. CONCLUSIONS: AALs are common but poorly documented in hospital records. Patients with AALs are significantly more likely to require alternative antibiotics, and hospital readmissions. There may be a role for antibiotic allergy delabelling to mitigate the clinical and economic burdens for patients with invalid allergy labels.en_US
dc.subjectAllergyen_US
dc.subjectAntibioticen_US
dc.subjectDelabellingen_US
dc.subjectDrug Hypersensitivityen_US
dc.subjectPenicillinen_US
dc.titleThe revolving door: antibiotic allergy labelling in a tertiary care centreen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleInternal Medicine Journalen_US
dc.identifier.affiliationDepartment of Clinical Immunology, Royal Perth Hospital, Wellington St, Perth, Western Australia, Australiaen_US
dc.identifier.affiliationDepartment of Clinical Immunology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australiaen_US
dc.identifier.affiliationDepartment of Research, Sir Charles Gairdner Hospital, Perth, Western Australia, Australiaen_US
dc.identifier.affiliationCentre for Applied Statistics, University of Western Australia, Perth, Western Australia, Australiaen_US
dc.identifier.affiliationDepartment of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Immunology, Royal Adelaide Hospital, Adelaide, South Australia, Australiaen_US
dc.identifier.affiliationHarry Perkins Institute of Medical Research, Perth, Western Australia, Australiaen_US
dc.identifier.affiliationAustralasian Society of Clinical Immunology and Allergy, Sydney, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Clinical Immunology, Princess Margaret Hospital, Perth, Western Australia, Australiaen_US
dc.identifier.affiliationPathwest laboratory, Queen Elizabeth II Campus, Perth, Western Australia, Australiaen_US
dc.identifier.affiliationInstitute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27530619en_US
dc.identifier.doi10.1111/imj.13223en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherTrubiano, Jason-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptCentre for Antibiotic Allergy and Research-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

54
checked on Nov 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.